Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 1/2015

01.01.2015 | Pediatric Hypertension (B Falkner, Section Editor)

Treatment of Hypertension in Children with Chronic Kidney Disease

Erschienen in: Current Hypertension Reports | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Hypertension (HTN) is increasingly recognized as a common feature of pediatric chronic kidney disease (CKD). A growing body of evidence demonstrates that HTN is both underdiagnosed and undertreated in this population. The consequences of untreated HTN include adverse effects on CKD progression, markers of cardiovascular morbidity, and neurocognitive functioning. Consensus guidelines issued over the past decade have incorporated recent research on the consequences of HTN in recommendations for the diagnosis and treatment of HTN in pediatric CKD and include lower BP targets. Agents which target the renin-angiotensin-aldosterone system (RAAS) should be considered first-line therapy in CKD-associated HTN in children, though multiple medications may be required to achieve sufficient BP control.
Literatur
1.
U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2013. Available at: http://​www.​usrds.​org/​adr.​aspx. Accessed 25 Aug 2014.
2.
Gupta-Malrotra M, Banker A, Shete S. Essential hypertension vs. secondary hypertension among children. Am J Hypertens. 2014.
3.
Din-Dzietham R, Liu Y, Bielo MV, et al. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. 2007;116:1488–96.CrossRefPubMed
4.
McNiece KL, Poffenbarger TS, Turner JL, et al. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr. 2007;150:640–4.CrossRefPubMed
5.
Mitsnefes M, Ho P-L, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol. 2003;14:2618–22.CrossRefPubMed
6.•
Flynn JT, Mitsnefes M, Pierce C, et al. Blood pressure in children with chronic kidney disease. Hypertension. 2008;52:631–7. Demonstrated high prevalence of untreated hypertension in children with mild-to-moderate CKD. CrossRefPubMedCentralPubMed
7.••
Samuels J, Ng D, Flynn JT, et al. Ambulatory blood pressure patterns in children with chronic kidney disease. Hypertension. 2012;60:43–50. Using ambulatory BP monitoring, this study demonstrated a high prevalence of masked hypertension in children with CKD, particularly while asleep. CrossRefPubMedCentralPubMed
8.
Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension. 2014;63:1116–35.CrossRefPubMed
9.
Kavey RW, Allade V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science: The Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation. 2006;114:2710–38.CrossRefPubMed
10.
Parekh RS, Carroll CE, Wolfe RA, et al. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr. 2002;141:191–7.CrossRefPubMed
11.
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.CrossRef
12.••
Halbach SM, Martz K, Mattoo T, et al. Predictors of blood pressure and its control in pediatric patients receiving dialysis. J Pediatr. 2012;160:621–625.j. Registry study showing trends in blood pressure control over time in US pediatric dialysis patients and factors contributing to poor control. CrossRefPubMedCentralPubMed
13.
Chavers BM, Solid CA, Daniels FX, et al. Hypertension in pediatric long-term hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2009;4:1363–9.CrossRefPubMedCentralPubMed
14.••
Kramer AM, van Stralen KJ, Jager KJ, et al. Demographics of blood pressure and hypertension in children on renal replacement therapy in Europe. Kidney Int. 2011;80:1092–8. Large-scale registry study showing high prevalence of untreated hypertension in European children on dialysis and following renal transplant. CrossRefPubMed
15.
Sorof JM, Sullivan EK, Tejani A, et al. Antihypertensive mediation and renal allograft failure: a North American Renal Transplant Cooperative Study report. J Am Soc Nephrol. 1999;10:1324–30.PubMed
16.
Sinha MD, Kerecuk L, Gilg J, et al. Systemic arterial hypertension in children following renal transplantation: prevalence and risk factors. Nephrol Dial Transplant. 2012;27:3359–68.CrossRefPubMed
17.•
Seeman T, Simkova E, Kreisinger J, et al. Control of hypertension in children after renal transplant. Pediatr Transplant. 2006;10:316–22. Single-center study demonstrating significance of post-transplant hypertension in pediatric transplant recipients. CrossRefPubMed
18.
Gulhan B, Topaloglu R, Karabulut E, et al. Post-transplant hypertension in pediatric kidney transplant recipients. Pediatr Nephrol. 2014;29:1075–80.CrossRefPubMed
19.
McGlothan KR, Wyatt RJ, Ault BH, et al. Predominance of nocturnal hypertension in pediatric renal allograft recipients. Pediatr Transplant. 2006;10:558–64.CrossRefPubMed
20.
Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;34:13–8.CrossRef
21.
Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–62.CrossRefPubMed
22.
Wingen AM, Fabian-Bach C, Schaefer F, et al. Randomized multi-centre study of a low-protein diet on the progression of chronic renal failure in children. Lancet. 1997;349:1117–23.CrossRefPubMed
23.•
Staples AO, Greenbaun LA, Smith JM, et al. Association between clinical risk factors and progression of chronic kidney disease in children. Clin J Am Soc Nephrol. 2010;5:2172–9. Illustrates importance of high blood pressure among other factors in progression of pediatric chronic kidney disease. CrossRefPubMedCentralPubMed
24.
Ksiazek A, Klosowska J, Sygulla K, et al. Arterial hypertension and progression of chronic kidney disease in children during 10-year ambulatory observation. Clin Exp Hypertens. 2013;35:424–9.CrossRefPubMed
25.
Furth S, Flynn J, Pierce C, et al. Lower systolic BP associated with slower CKD progression in the CKiD Study (abstract). J Am Soc Nephrol. 2010;21:551A.CrossRef
26.
National Kidney Foundation. KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1–S290.
27.
Becker GJ, Wheeler DC. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012;2:S337–414.CrossRef
28.••
Kogon AJ, Pierce CB, Cox C, et al. Nephrotic-range proteinuria is strongly associated with poor blood pressure control in pediatric chronic kidney disease. Kidney Int. 2014;85:938–44. Another study from the CKiD investigators illustrating the influence of proteinuria on blood pressure control in pediatric chronic kidney disease. CrossRefPubMedCentralPubMed
29.
Johnstone LM, Jones CL, Grigg LE, et al. Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int. 1996;50:998–1006.CrossRefPubMed
30.
Matteucci MC, Wuhl E, Picca S, et al. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol. 2006;17:218–26.CrossRefPubMed
31.
Sinha MD, Tibby SM, Rasmussen P, et al. Blood pressure control and left ventricular mass in children with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:543–51.CrossRefPubMedCentralPubMed
32.•
Mitsnefes M, Flynn J, Cohn S, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. Clin J Am Soc Nephrol. 2010;21:137–44. This study showed that left ventricular hypertrophy was common in children with chronic kidney disease who have masked hypertension on ABPM. CrossRef
33.
Simpson JM, Savis A, Rawlins D, et al. Incidence of left ventricular hypertrophy in children with kidney disease: impact of method of indexation of left ventricular mass. Eur J Echocardiogr. 2010;11:271–7.CrossRefPubMed
34.••
Matteucci MC, Chinali M, Rinelli G, et al. Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. Clin J Am Soc Nephrol. 2013;8:203–10. Data from the ESCAPE study showing effect of strict blood pressure control on left ventricular hypertrophy. CrossRefPubMedCentralPubMed
35.
Kupferman JC, Friedman LA, Cox C, et al. BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol. 2014;25:167–74.CrossRefPubMedCentralPubMed
36.
Mitsnefes MM, Kimball TR, Kartal J, et al. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. J Am Soc Nephrol. 2005;16:2796–803.CrossRefPubMed
37.
Litwin M, Wuhl E, Jourdan C, et al. Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. Nephrol Dial Transplant. 2008;23:2552–7.CrossRefPubMed
38.
Brady TM, Schneider MF, Flynn JT, et al. Carotid intima-media thickness in children with CKD: results from the CKiD study. Clin J Am Soc Nephrol. 2012;7:1930–7.CrossRefPubMedCentralPubMed
39.
Lande MB, Kaczorowski JM, Auinger P, et al. Elevated blood pressure and decreased cognitive function among school-age children and adolescents in the United States. J Pediatr. 2003;143:720–4.CrossRefPubMed
40.
Lande MB, Adams H, Falkner B, et al. Parental assessments of internalizing and externalizing behavior and executive function in children with primary hypertension. J Pediatr. 2009;154:207–12.CrossRefPubMedCentralPubMed
41.
Lande MB, Adams H, Falkner B, et al. Parental assessment of executive function and internalizing and externalizing behavior in primary hypertension after anti-hypertensive therapy. J Pediatr. 2010;157:114–9.CrossRefPubMedCentralPubMed
42.
Hooper SR, Gerson AC, Butler RW, et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:1824–30.CrossRefPubMedCentralPubMed
43.
Lande MB, Gerson AC, Hooper SR, et al. Casual blood pressure and neurocognitive function in children with chronic kidney disease: a report of the children with chronic kidney disease cohort study. Clin J Am Soc Nephrol. 2011;6:1831–7.CrossRefPubMedCentralPubMed
44.••
The ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361:1639–50. Landmark study showing that lower blood pressure is associated with slower progression of renal insufficiency in children with chronic kidney disease. CrossRef
45.
Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719–42.CrossRefPubMed
46.
Gorostidi M, Sarafidis PA, de la Sierra A, et al. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5693-patient cross-sectional analysis from Spain. Am J Kidney Dis. 2013;62:285–94.CrossRefPubMed
47.
Cha RH, Kim S, Ae YS, et al. Association between blood pressure and target organ damage in patients with chronic kidney disease and hypertension: results of the APrODiTe study. Hypertens Res. 2013;37:172–8.CrossRefPubMed
48.
Gabbai FB, Rahman M, Hu B, et al. Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD. Clin J Am Soc Nephrol. 2012;7:1770–6.CrossRefPubMedCentralPubMed
49.
Fedecostante M, Spannella F, Cola G, et al. Chronic kidney disease is characterized by “double trouble” higher pulse pressure plus night-time systolic blood pressure and more severe cardiac damage. PLoS One. 2014;9(1):e86155.CrossRefPubMedCentralPubMed
50.
Yano Y, Bakris GL, Matsushita K, et al. Both chronic kidney disease and nocturnal blood pressure associate with strokes in elderly. Am J Nephrol. 2013;38:195–203.CrossRefPubMed
51.
Gartenmann AC, Fossali E, von Vigier RO, et al. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int. 2003;64:1450–4.CrossRefPubMed
52.
Ferguson M, Flynn JT. Rational use of antihypertensive medications in children. Pediatr Nephrol. 2014;29:979–88.CrossRefPubMed
53.
The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.CrossRef
54.
Wright Jr JT, Bakris G, Greene T, et al. African American study of kidney disease and hypertension: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2003;288:2421–31.CrossRef
55.
Sullivan JE, Keefe D, Zhou Y, et al. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Clin Pediatr. 2013;52:599–607.CrossRef
56.
Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42.CrossRefPubMedCentralPubMed
Metadaten
Titel
Treatment of Hypertension in Children with Chronic Kidney Disease
Publikationsdatum
01.01.2015
Erschienen in
Current Hypertension Reports / Ausgabe 1/2015
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-014-0503-3

Weitere Artikel der Ausgabe 1/2015

Current Hypertension Reports 1/2015 Zur Ausgabe

Hypertension and Obesity (E Reisin, Section Editor)

Hypertension and Insulin Resistance: Implications of Mitochondrial Dysfunction

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Plasma Renin Testing to Guide Antihypertensive Therapy

Pediatric Hypertension (B Falkner, Section Editor)

Cognitive Function in Hypertensive Children

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Preventing the Progression of Prehypertension to Hypertension: Role of Antihypertensives

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Vasopressin Receptor Antagonists

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise